Cytogenetic and proteomic prognostic markers of CLL
Cytogenetic and proteomic prognostic markers of CLL
Predicting progression and survival in CLL
Expert panel discussion: The best of iwCLL 2015
Harmonisation of CLL diagnosis and detection of residual disease monitoring by flow cytometry
Primary results from the MABLE phase IIIb study
Results of subgroup analysis of the HELIOS trial
Results of a new phase Ib trial of voxtalisib in combination with chemoimmunotherapy
Highlights from the iwCLL conference: B-cell receptor Btk, PI3K and multi-molecular BCR inhibitors
History of the B-cell in its 50th anniversary year
Human B-cell receptor structure and function in CLL
Translational research and the future of CLL treatment
The p-medicine project and ECRIN